Early feasibility vs pivotal trial: which comes first for a medical device?

Sponsors keep asking whether an early feasibility study or a pivotal trial comes first as if the answer were a preference. It is not. For a novel medical device, an early feasibility study (EFS) generally comes before a pivotal trial because the two studies answer different questions.

I am Julio Martinez-Clark, CEO of bioaccess®. This is the sequencing brief I reuse when a founder wants to jump straight to a powered pivotal. It sits next to the live Early Feasibility Studies pillar, the LATAM FIH startup clock, and the FDA acceptance of Latin American data note. It is not a quote and not legal advice.

One-sentence answer

An early feasibility study comes first when clinical safety, function, or design finality is still open. A pivotal trial comes later to collect definitive safety and effectiveness evidence for a specified intended use. Skip the EFS only when nonclinical evidence already closes those unknowns and the device design is frozen.

What each study is built to answer

An EFS is a limited clinical investigation conducted early in development. Enrollment is small. The job is initial clinical safety and feasibility evidence — proof the device can be used in humans without a surprise failure mode. The U.S. Food and Drug Administration (FDA) Early Feasibility Studies Program is the U.S. framing for that IDEA under an Investigational Device Exemption (IDE) in 21 CFR Part 812.

A pivotal study is sized and powered for definitive endpoints. It assumes the device design is stable, the primary endpoint is known, and the statistical analysis plan can be written with real assumptions. If you are still learning what the right endpoint is, a pivotal protocol will be mis-scoped.

Four decision nodes

1. Risk class and novelty. Higher-risk implants and first-in-class mechanisms carry more human uncertainty. When nonclinical data alone cannot justify definitive effectiveness endpoints, EFS-first is the honest path.

2. Preclinical maturity and design finality. Is the GLP / bench / animal package enough to characterize primary safety risks? Is the device design frozen? If either answer is no, stay in EFS.

3. Funding runway. Pivotal enrollment is larger and slower. If the next financing round needs human evidence this year, a small EFS can deliver proof-of-principle without burning the pivotal budget early. That is planning math, not a guarantee.

4. Intended U.S. pathway. Map the study to the 510(k), De Novo, or Premarket Approval (PMA) evidence role you actually need. EFS does not replace pivotal evidence. A well-designed EFS can refine endpoints, validate risk controls, and feed the assumptions your later statistical analysis plan will use.

When a direct pivotal path can make sense

Lower-risk devices with a frozen design, a complete nonclinical package, and enough runway for a powered study can sometimes go straight to pivotal (or a traditional feasibility study if a thin clinical gap remains). Adding an EFS stage in that case delays marketing authorization without generating meaningfully new information.

How Latin America fits the EFS step

Many U.S. MedTech teams run the early human evidence step outside the United States, then bring a cleaner package into the U.S. IDE or marketing file. Foreign clinical data can be considered under 21 CFR 812.28 when the study is inspectable and conducted under good clinical practice. ISO 14155 is the device GCP standard we design to. Acceptance is still FDA’s call per submission — there is no automatic transfer.

In Latin America, ethics-committee review for device FIH / EFS work commonly lands in a planning band of about 4–8 weeks, and in-country investigation authorization often follows in roughly 1–3 months depending on country and dossier quality. Those are experience-based ranges from bioaccess® programs since 2010, not a promise for your protocol. The startup clock page keeps the country bands in one place.

Documentation to lock before first patient

• Protocol with an explicit evidence-role statement (what this study must do for the next regulatory or financing milestone)
• Informed consent aligned to the local ethics committee
• Monitoring and quality plan with deviation tracking
• Data management plan with source-document traceability
• Clinical study report structure and analysis framework ready at study start, not after database lock

Operator checklist

1. Write answers to the four decision nodes in one page.
2. List preclinical gaps before you pick study type.
3. Draft the evidence-role sentence your protocol will carry.
4. If EFS-first, choose the country corridor for ethics speed and cardiac or procedure infrastructure — not for tourism.
5. If you already have human feasibility evidence and a frozen design, stop debating EFS and scope the pivotal honestly.

Talk with bioaccess® when you need the sequencing call tied to a concrete FIH or EFS country plan and an FDA-anchored evidence drawer.